Adalimumab, a drug often prescribed for women with Crohn’s disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn’s bloodstream for at least three months, researchers have found.
Adalimumab, a drug often prescribed for women with Crohn’s disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn’s bloodstream for at least three months, researchers have found.